Dr. Bunn on Current Role of Precision Medicine for Lung Cancer

Paul A. Bunn, Jr, MD
Published: Friday, Jan 06, 2017



Paul A. Bunn, Jr, MD, professor of Medicine in Medical Oncology, head of the Division of Medical Oncology at the University of Colorado, discusses the current role of precision medicine in lung cancer.

Bunn explains that there are several biomarkers that can predict which therapy is going to be most beneficial as a patient begins treatment. Since there are multiple molecular biomarkers, it is easier and more cost effective to execute them all at the same time by utilizing next-generation sequencing (NGS). It has now become standard for patients with adenocarcinoma to do NGS testing first.

Looking at PD-L1 expression by immunohistochemistry has also become an important, standard step prior to beginning treatment, he explains. Studies have shown that if more than 49% of tumor cells express PD-L1, pembrolizumab (Keytruda) can be a superior treatment to chemotherapy.
 
SELECTED
LANGUAGE


Paul A. Bunn, Jr, MD, professor of Medicine in Medical Oncology, head of the Division of Medical Oncology at the University of Colorado, discusses the current role of precision medicine in lung cancer.

Bunn explains that there are several biomarkers that can predict which therapy is going to be most beneficial as a patient begins treatment. Since there are multiple molecular biomarkers, it is easier and more cost effective to execute them all at the same time by utilizing next-generation sequencing (NGS). It has now become standard for patients with adenocarcinoma to do NGS testing first.

Looking at PD-L1 expression by immunohistochemistry has also become an important, standard step prior to beginning treatment, he explains. Studies have shown that if more than 49% of tumor cells express PD-L1, pembrolizumab (Keytruda) can be a superior treatment to chemotherapy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x